Professional
Added to YB: 2026-07-22
Pitch date: 2026-07-18
LQDA [neutral]
Liquidia Corporation
+1.16%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$7.1B
Pitch Price
$79.97
Price Target
140.00 (+82%)
Dividend
N/A
EV/EBITDA
147.57
P/E
327.46
EV/Sales
24.55
Sector
Pharmaceuticals
Category
special_situation
Arquitos Capital Management Portfolio Holding: Liquidia Corporation
LQDA (holding update): +540% YoY to $79.73 on blockbuster Yutrepia launch + Russell 2000 inclusion. Awaiting '327 patent trial ruling (PH-ILD only) vs United Therapeutics, any day now. Values: clean win $140, royalty $123, worst case $70. Sees patent invalid as most likely; buyer on dips.
Read full article (2 min)